Results 21 to 30 of about 81,076 (308)

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

BMC Infectious Diseases, 2021
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz, Avi J. Cohen, Andre P. Rebaza, James Vanchieri, Martin D. Slade, Charles S. Dela Cruz, Lokesh Sharma   +6 more
doaj   +1 more source

Itch and Janus Kinase Inhibitors

Acta Dermato-Venereologica, 2023
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a
Yujin Han, Yu Ri Woo, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim   +4 more
openaire   +3 more sources

Acute retinal necrosis during the systemic use of Janus kinase inhibitor [PDF]

International Journal of Retina and Vitreous
Daisuke Watanabe, Kenichi Namba, Keitaro Hase, Kayo Suzuki, Yo Ogino, Michiyuki Saito, Daiju Iwata, Kazuomi Mizuuchi, Miki Hiraoka, Mao Narita, Nobuyoshi Kitaichi, Norihiko Kitaya, Susumu Ishida   +12 more
doaj   +2 more sources

Glucocorticoids combined with tofacitinib for systemic sarcoidosis with rash as initial symptom: a case report [PDF]

Xin yixue, 2023
Systemic sarcoidosis is a granulomatous disease involving multiple organs and systems. A 36-year-old woman was admitted due to multiple nodules of the trunk for 4 months. Upon admission， laboratory and auxiliary examinations were performed.
Hu Rongrong, Hong Yixin, Su Xiangyang, Ma Guiyan, Chen Peiran
doaj   +1 more source

Effectiveness of upadacitinib in Japanese patients with prurigo‐type atopic dermatitis: Four cases report

Journal of Cutaneous Immunology and Allergy, 2023
We present four Japanese patients with prurigo‐type AD who received upadacitinib. Rapid improvement of skin lesions and itchiness was seen in all patients. Janus kinase inhibitor is effective for prurigo‐type AD by strongly suppressing itching.
Keiji Kosaka, Akihiko Uchiyama, Mai Ishikawa, Sei‐ichiro Motegi   +3 more
doaj   +1 more source

Janus kinase inhibitors in autoimmune diseases [PDF]

Annals of the Rheumatic Diseases, 2013
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea, Apostolos, Kontzias, Kunihiro, Yamaoka, Yoshiya, Tanaka, Arian, Laurence   +4 more
openaire   +2 more sources

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

SAGE Open Medical Case Reports, 2023
Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj   +1 more source

In silico method potential therapeutic use of Janus Kinase inhibitors as severe acute respiratory syndrome coronavirus 2 main protease inhibitors

Journal of the Scientific Society, 2023
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge, Sushmita I Hiremath, Akshata S Menasinakai, Mahesh S Palled   +3 more
doaj   +1 more source

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
openaire   +3 more sources